Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 819548, 10 pages
http://dx.doi.org/10.1155/2014/819548
Research Article

The Connection between the Toxicity of Anthracyclines and Their Ability to Modulate the P-Glycoprotein-Mediated Transport in A549, HepG2, and MCF-7 Cells

1Department of Thermobiology, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143 Street, 90-236 Lodz, Poland
2Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143 Street, 90-236 Lodz, Poland

Received 26 August 2013; Accepted 29 October 2013; Published 19 January 2014

Academic Editors: D. A. Altomare and D. Rossi

Copyright © 2014 Aneta Rogalska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. B. Chung, J. E. Yi, J. Y. Jin et al., “Early cardiac function monitoring for detection of subclinical Doxorubicin cardiotoxicity in young adult patients with breast cancer,” Journal of Breast Cancer, vol. 16, no. 2, pp. 178–183, 2013. View at Publisher · View at Google Scholar
  2. J. Dudka, “The role of reactive oxygen and nitrogen species in calcium and iron homeostasis dysregulation in anthracycline cardiotoxicity,” Postepy Higieny i Medycyny Doswiadczalnej, vol. 60, pp. 241–247, 2006. View at Google Scholar · View at Scopus
  3. Y.-L. Lo, Y. Liu, and J.-C. Tsai, “Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo,” Biomedicine & Pharmacotherapy, vol. 67, no. 4, pp. 261–267, 2013. View at Publisher · View at Google Scholar
  4. T. Kubo, N. Takigawa, M. Osawa et al., “Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy,” Cancer Science, vol. 104, no. 1, pp. 78–84, 2013. View at Publisher · View at Google Scholar
  5. B. M. Gruber, E. L. Anuszewska, I. Bubko, A. Goździk, I. Fokt, and W. Priebe, “Effect of structural modification at the 4, 3′, and 2′ positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells,” Archivum Immunologiae et Therapiae Experimentalis, vol. 55, no. 3, pp. 193–198, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. F. J. Sharom, “ABC multidrug transporters: structure, function and role in chemoresistance,” Pharmacogenomics, vol. 9, no. 1, pp. 105–127, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. M. M. Gottesman and V. Ling, “The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research,” FEBS Letters, vol. 580, no. 4, pp. 998–1009, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Sandor, T. Fojo, and S. E. Bates, “Future perspectives for the development of P-glycoprotein modulators,” Drug Resistance Updates, vol. 1, no. 3, pp. 190–200, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Hajji, S. Mateos, N. Pastor, I. Domínguez, and F. Cortés, “Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor,” Mutation Research, vol. 583, no. 1, pp. 26–35, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. H. H. Zhu, H. Jiang, B. Jiang et al., “Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy,” Leukemia & lymphoma, vol. 54, no. 11, pp. 2452–2457, 2013. View at Publisher · View at Google Scholar
  11. X. Zhang, Y. Li, Y. Zhang et al., “Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: a multicenter, randomized control trial in southwest China,” Leukemia & lymphoma, vol. 37, no. 6, pp. 657–664, 2013. View at Publisher · View at Google Scholar
  12. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni, “Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity,” Pharmacological Reviews, vol. 56, no. 2, pp. 185–229, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. H.-Y. Li, H. Yue, X.-D. Wei et al., “The efficacy of high-dose cytarabine for patients with t(8;21) AML and with normal karyotype AML,” Zhonghua Xue Ye Xue Za Zhi, vol. 29, no. 2, pp. 110–112, 2008. View at Google Scholar · View at Scopus
  14. V. D. Baldissera, A. A. de Mattos, G. P. Coral et al., “Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma,” Annals of Hepatology, vol. 11, no. 6, pp. 899–906, 2012. View at Google Scholar
  15. G. Lehne, P. De Angelis, O. P. F. Clausen, and H. E. Rugstad, “Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines,” British Journal of Cancer, vol. 74, no. 11, pp. 1719–1729, 1996. View at Google Scholar · View at Scopus
  16. H. M. Coley, P. R. Twentyman, and P. Workman, “Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A,” Biochemical Pharmacology, vol. 38, no. 24, pp. 4467–4475, 1989. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Schwab, H. Fischer, A. Tabatabaei, S. Poli, and J. Huwyler, “Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery,” Journal of Medicinal Chemistry, vol. 46, no. 9, pp. 1716–1725, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Chaoui, A.-M. Faussat, P. Majdak et al., “JC-1, a sensitive probe for a simultaneous detection of P-glycoprotein activity and apoptosis in leukemic cells,” Cytometry: Part B, vol. 70, no. 3, pp. 189–196, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Zhou, P. Shen, and Y. Cheng, “Quantitative study of the drug efflux kinetics from sensitive and MDR human breast cancer cells,” Biochimica et Biophysica Acta, vol. 1770, no. 7, pp. 1011–1020, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Galluzzi, N. Zamzami, T. D. L. M. Rouge, C. Lemaire, C. Brenner, and G. Kroemer, “Methods for the assessment of mitochondrial membrane permeabilization in apoptosis,” Apoptosis, vol. 12, no. 5, pp. 803–813, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Rogalska, M. Szwed, and Z. Jóźwiak, “Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours,” Mutation Research, vol. 700, no. 1-2, pp. 1–10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Rogalska, A. Koceva-Chyła, and Z. Jóźwiak, “Aclarubicin-induced ROS generation and collapse of mitochondrial membrane potential in human cancer cell lines,” Chemico-Biological Interactions, vol. 176, no. 1, pp. 58–70, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Barraud, P. Merle, E. Soma et al., “Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo,” Journal of Hepatology, vol. 42, no. 5, pp. 736–743, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Li, A. C. Jiang, P. Dong, Y. Wan, and Z. W. Yu, “The characteristics of Hep-2 cell with multiple drug resistance induced by Taxol,” Otolaryngology, vol. 137, no. 4, pp. 659–664, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Azzariti, N. A. Colabufo, F. Berardi et al., “Cyclohexylpiperazine derivative PB28, a σ2 agonist and σ1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer,” Molecular Cancer Therapeutics, vol. 5, no. 7, pp. 1807–1816, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Lo, B. Tolner, J.-W. Taanman et al., “Assessment of the significance of mitochondrial DNA damage by chemotherapeutic agents,” International Journal of Oncology, vol. 27, no. 2, pp. 337–344, 2005. View at Google Scholar · View at Scopus
  27. Z. T. Krasznai, Á. Tóth, P. Mikecz et al., “Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG,” European Journal of Pharmaceutical Sciences, vol. 41, no. 5, pp. 665–669, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. G. L. Scheffer, A. C. L. M. Pijnenborg, E. F. Smit et al., “Multidrug resistance related molecules in human and murine lung,” Journal of Clinical Pathology, vol. 55, no. 5, pp. 332–339, 2002. View at Google Scholar · View at Scopus
  29. A. Hira, H. Watanabe, Y. Maeda et al., “Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells,” Biochemical Pharmacology, vol. 75, no. 4, pp. 973–980, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Volm, J. Mattern, and B. Samsel, “Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170, and glutathione S-transferase-pi in human lung tumors,” Cancer, vol. 70, no. 4, pp. 764–769, 1992. View at Publisher · View at Google Scholar
  31. K. O. Hamilton, E. Topp, I. Makagiansar, T. Siahaan, M. Yazdanian, and K. L. Audus, “Multidrug resistance-associated protein-1 functional activity in Calu-3 cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 298, no. 3, pp. 1199–1205, 2001. View at Google Scholar · View at Scopus
  32. K. Yoh, G. Ishii, T. Yokose et al., “Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer,” Clinical Cancer Research, vol. 10, no. 5, pp. 1691–1697, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Merk, J. Rolff, C. Dorn, G. Leschber, and I. Fichtner, “Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?” European Journal of Cardio-Thoracic Surgery, vol. 40, no. 1, pp. e29–e33, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Okuyama, Y. Maehara, K. Endo et al., “Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin,” Cancer, vol. 74, no. 4, pp. 1230–1236, 1994. View at Publisher · View at Google Scholar
  35. S. Nakamura, T. Takeichi, C. Yamanaka et al., “Multiple hepatocellular carcinomas developed 15 months after commencement of chemotherapy for elderly acute myelogenous leukemia,” Rinshō ketsueki, vol. 50, no. 11, pp. 1616–1620, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Akimoto, M. Yoshikawa, M. Ebara et al., “Relationship between therapeutic efficacy of arterial infusion chemotheraphy and expression of P-glycoprotein and p53 protein in advanced hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 12, no. 6, pp. 868–873, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. Z. Sun, Z. Zhao, G. Li et al., “Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies,” Tumori, vol. 96, no. 1, pp. 90–96, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Burger, J. A. Foekens, M. P. Look et al., “RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response,” Clinical Cancer Research, vol. 9, no. 2, pp. 827–836, 2003. View at Google Scholar · View at Scopus
  39. A. M. Calcagno, J. M. Fostel, K. K. W. To et al., “Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes,” British Journal of Cancer, vol. 98, no. 9, pp. 1515–1524, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. L. D. Cripe, H. Uno, E. M. Paietta et al., “Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999,” Blood, vol. 116, no. 20, pp. 4077–4085, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. H.-B. Xu, L. Li, J. Fu, X.-P. Mao, and L.-Z. Xu, “Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by beta-elemene,” Pharmacology, vol. 89, pp. 303–312, 2012. View at Publisher · View at Google Scholar